Seminoma Clinical Trial
Official title:
THERApy De-escalation for TESTicular Cancer
THERATEST is looking to collect data from 30 patients actively receiving de-escalation treatments or other standard of care treatments in two UK hospitals. THERATEST is a feasibility study to determine whether patients are willing to be recruited, the impact of de-escalation treatments on patients' cancers and quality of life, whether we should proceed with these treatments in a larger study, and if so how the study should be conducted. A feasibility study prepares the ground for a larger study and improves the chances of the subsequent study producing valuable evidence, and helps to avoid wasting precious resources on larger trials that are unlikely to be informative. We hope that information from THERATEST will bridge the current knowledge gap and allow clinicians to design bigger trials to actively compare the different treatment strategies.
THERATEST is an observational cohort study of patients receiving SOC treatments (combination chemotherapy or radiotherapy) or de-escalated treatments (primary rRPLND or Carboplatin AUC10) treatments for stage II seminoma. Potential patients will be identified and invited to join the THERATEST study. Patients will be allocated to the following cohorts based on whether the relevant mode of treatment is adopted as an institutional SOC in their respective institution: A. rRPLND cohort: Patients with seminoma who are negative/low for tumour markers and unifocal ipsilateral Stage IIA or <3cm IIB will be assessed for rRPLND. Patients who are eligible for rRPLND will undergo surgery followed by adjuvant treatment or surveillance as determined by their clinical teams based on post-operative histology as per SOC. Patients who are not deemed eligible for or decline rRPLND, will be offered either BEP/EP chemotherapy or radiotherapy with or without neoadjuvant Carboplatin AUC7 and will continue to be followed in the study. B. Carboplatin AUC10 cohort: Patients with stage II seminoma will be offered Carboplatin AUC10. Those deemed ineligible for Carboplatin AUC10 or who decline this treatment option will be offered either BEP/EP chemotherapy or radiotherapy and will continue to be followed in the study. Chemotherapy treatment strategies and adjuvant treatments are left to the shared decision-making between treating clinician and patient and follow institutional SOC. In both cohorts patients will be followed up for 2 years after treatment completion or until death or withdrawal of consent, whichever is the earliest. Beyond the study period, patients will be follow up as per institutional SOC protocols as part of prospective institutional audits. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06133543 -
Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer
|
N/A | |
Recruiting |
NCT05529251 -
De-escalation Study for Stage IIa/IIb < 3 cm Seminoma
|
Phase 2 | |
Completed |
NCT00705094 -
Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients
|
N/A | |
Active, not recruiting |
NCT03158064 -
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
|
Phase 2 | |
Recruiting |
NCT01887340 -
Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma
|
Phase 2 | |
Active, not recruiting |
NCT01593241 -
Therapy De-escalation in Seminoma Stage IIA/B
|
Phase 2 | |
Recruiting |
NCT04876456 -
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
|
Phase 2 | |
Active, not recruiting |
NCT03937843 -
Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma
|
Phase 2 | |
Recruiting |
NCT04435756 -
A Study of miRNA 371 in Patients With Germ Cell Tumors
|
||
Active, not recruiting |
NCT02834013 -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
|
Phase 2 | |
Recruiting |
NCT04914026 -
MicroRNA as Markers in Testicular Cancer
|
||
Not yet recruiting |
NCT05142982 -
Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced Seminoma
|
N/A | |
Active, not recruiting |
NCT02375204 -
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
|
Phase 3 | |
Recruiting |
NCT06144736 -
PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND
|
Phase 2 | |
Recruiting |
NCT02341989 -
Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer
|
Phase 3 |